Tesamorelin (5 mg Vial) Dosage Protocol

Tesamorelin (5 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the pituitary, resulting in increased IGF-1, reduced visceral adipose tissue, and improved body composition.[1] It is FDA-approved as Egrifta SV for HIV-associated lipodystrophy at 2 mg/day.

  • Reconstitute: Add 2.5 mL bacteriostatic water → 2.0 mg/mL concentration.
  • Standard dose: 1–2 mg once daily subcutaneously in the evening.
  • Easy measuring: At 2.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 20 mcg. A 1 mg dose = 50 units / 0.50 mL; a 2 mg dose = 100 units / 1.00 mL.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 3 weeks.
Tesamorelin 5mg Vial

Dosing & Reconstitution Guide

Educational protocol for once-daily evening subcutaneous tesamorelin injection

Daily Protocol (2.5 mL = 2.0 mg/mL)

Dose Units (U-100) Volume Frequency Vial Duration
1 mg (research starting dose) 50 units 0.50 mL Once daily, evening 5 days per vial
2 mg (FDA-approved / standard) 100 units 1.00 mL Once daily, evening 2.5 days per vial

At the standard 2 mg/day research dose, the 5 mg vial (reconstituted in 2.5 mL) provides 2.5 doses. Plan to purchase multiple vials for a sustained protocol. A 4-week cycle at 2 mg/day requires 56 mg total → approximately 12 vials. Evening dosing aligns with the body’s natural overnight GH pulse to amplify the response.[2]

Reconstitution Steps

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 2.5 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; do not inject directly onto the lyophilised cake.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 3 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4-week cycle at 2 mg/day (28 injections, 56 mg total).

  • Tesamorelin Vials (5 mg each): 56 mg needed ÷ 5 mg per vial → 12 vials.
  • Insulin Syringes (U-100, 1 mL): 28 injections → 28 syringes.
  • Bacteriostatic Water (10 mL bottles): 2.5 mL per vial → 1 × 10 mL bottle covers 4 vials.
  • Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.
Tesamorelin 5mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Goal: Reduce visceral adipose tissue and improve body composition via stimulated pulsatile GH secretion and downstream IGF-1 elevation.[1]
  • Schedule: Once-daily subcutaneous injection in the evening (to align with natural GH pulsatility).
  • Dose range: 1–2 mg per day; 2 mg is the FDA-approved clinical dose.
  • Reconstitution: 2.5 mL BAC water per 5 mg vial → 2.0 mg/mL.
  • Cycle: Assess body composition and IGF-1 levels at 12 weeks.

Dosing Protocol

  • Research start: 1 mg (50 units / 0.50 mL) once daily in the evening for Weeks 1–2.
  • Standard dose: 2 mg (100 units / 1.00 mL) once daily in the evening from Week 3+.[1]
  • Injection site: Abdomen subcutaneous; rotate sites to avoid lipohypertrophy.
  • Cycle length: Minimum 12 weeks to assess visceral fat reduction; continue if tolerated and response is positive.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 3 weeks (tesamorelin is slightly less stable than some peptides post-reconstitution).
  • Appearance: Clear, colourless solution. Discard if cloudy or particulate.

Important Notes

  • Inject in the evening to align with the body’s natural overnight GH secretion pulse and maximise pituitary stimulation.[2]
  • Monitor fasting glucose — GH can reduce insulin sensitivity; periodic glucose checks are advisable for individuals with metabolic risk.
  • WADA-prohibited (Category S2: Peptide Hormones, Growth Factors) — athletes under anti-doping rules must not use tesamorelin.
  • Abdominal injection is preferred — tesamorelin was FDA-approved specifically for visceral fat reduction and abdominal injection maximises local effect.

How This Works

Tesamorelin is a synthetic conjugate of the full 44-amino acid GHRH (growth hormone-releasing hormone) sequence with a trans-3-hexenoic acid moiety that stabilises the peptide against plasma dipeptidyl peptidase IV (DPP-IV) degradation, extending its effective half-life.[3]

On binding pituitary GHRH receptors, tesamorelin stimulates pulsatile GH release in a physiologically appropriate pattern — unlike exogenous GH, which suppresses natural pulsatility. Increased GH drives hepatic and peripheral IGF-1 production, which promotes lipolysis in visceral adipocytes (reducing trunk fat), stimulates protein synthesis, and supports lean body mass. The net effect is a shift in body composition toward reduced visceral adipose tissue and preserved or increased lean mass.[1]

Potential Benefits & Considerations

  • Visceral fat reduction: Falutz et al. (2010 NEJM): tesamorelin 2 mg/day for 26 weeks reduced trunk fat by 15.2% vs. 1.6% placebo in HIV-associated lipodystrophy.[2]
  • IGF-1 elevation: Significant increases in serum IGF-1 in all major trials; typically normalises IGF-1 in GH-deficient adults.
  • Lean body mass: Modest preservation or improvement in lean mass alongside fat loss.
  • Side effects: Fluid retention, arthralgia, peripheral oedema, and myalgia occur in a minority of users — dose reduction mitigates these effects.
  • Glucose: GH-mediated insulin resistance is possible; monitor fasting glucose particularly in pre-diabetic individuals.

Lifestyle Factors

  • Pair with a calorie-controlled diet and resistance training to maximise and maintain body-composition improvements.
  • Fasted evening injection (≥2 hours after last meal) avoids insulin-driven blunting of the GH pulse.
  • Track waist circumference, fasting glucose, and IGF-1 (if available) at 6 and 12 weeks.
  • Adequate sleep is essential — tesamorelin’s mechanism synergises with sleep-related GH release.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • FDA — Egrifta SV (tesamorelin for injection) Prescribing Information
    — Official US labelling: 2 mg/day SC for HIV-associated lipodystrophy; pharmacokinetics, dosing, safety data
    View Source

  • Falutz J et al. — NEJM (2010)
    — Tesamorelin 2 mg/day for 26 weeks: 15.2% reduction in trunk fat vs. 1.6% placebo in HIV-associated lipodystrophy (Phase III RCT)
    View Source

  • Dhillon S — Drugs (2011)
    — Tesamorelin: a review of its use in HIV-associated lipodystrophy; mechanism, pharmacokinetics, and clinical evidence
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source